Nurix Therapeutics (NRIX) Other Working Capital Changes (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Other Working Capital Changes data on file, last reported at -$1.3 million in Q1 2026.

• Other Working Capital Changes for Q1 2026 came in at -$1.3 million, down 120.59% year-over-year; the trailing twelve-month figure through Feb 2026 was -$12.6 million (up 39.51% YoY), and the FY2025 annual result was -$5.1 million, up 82.25% from the prior year.
• Other Working Capital Changes climbed to -$1.3 million in Q1 2026 per NRIX's latest filing, from -$10.0 million in the prior quarter.
• Over five years, Other Working Capital Changes peaked at $8.0 million in Q3 2025 and troughed at -$27.8 million in Q4 2024.
• A 5-year average of -$2.4 million and a median of -$1.3 million in 2023 frame the typical range for Other Working Capital Changes.
• The sharpest annual moves came in 2024 and 2025: Other Working Capital Changes sank 1992.02% in 2024, then jumped 528.81% in 2025.
• A 5-year view of Other Working Capital Changes shows it stood at -$1.2 million in 2022, then retreated by 14.88% to -$1.3 million in 2023, then slumped by 1992.02% to -$27.8 million in 2024, then soared by 63.96% to -$10.0 million in 2025, then soared by 87.15% to -$1.3 million in 2026.
• Business Quant data shows NRIX's Other Working Capital Changes at -$1.3 million in Q1 2026, -$10.0 million in Q4 2025, and $8.0 million in Q3 2025.